Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 petosemtamab versus investigator's choice in previously treated metastatic or recurrent head and neck squamous cell carcinoma
NL-OMON58858Phase 3Active, not recruiting
- Sponsor
- Genmab
- Start
- Jan 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of petosemtamab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Genmab. Primary endpoint: Overall survival. Started Jan 2025; status: active, not recruiting.
02
Drugs
petosemtamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON58858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58858.